New Zealand Diabetes Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The New Zealand diabetes devices market is moving from a meter-and-strip model to a sensor-and-pump model. Public funding is the main lever, so each Pharmac decision reshapes which brands patients can use, which clinics support them and how suppliers plan stock.

Three forces are shaping the market: a growing patient base, with a peer-reviewed study published in January 2025 projecting 502,358 people with diabetes by the early 2040s; funded sensor access, with up to 40 Dexcom sensors or 28 FreeStyle Libre 2 Plus sensors a year; and supplier consolidation, as pump brands change owners.

In April 2025 Ypsomed agreed to sell its diabetes care business to TecMed AG, and in May 2025 Pharmac began funding the FreeStyle Libre 2 Plus. In October 2026 funding for MiniMed 770G consumables ended, completing a managed pump transition.

Key Market Trends and Insights

• Rising patient base: A peer-reviewed New Zealand study published in January 2025 projected 502,358 people with diabetes by the early 2040s, an 87% increase on the base period.
• Funded sensor access: Pharmac listed the FreeStyle Libre 2 Plus from 1 May 2025 with a limit of 28 sensors a year, while funded Dexcom sensors allow up to 40 a year.
• Pump transition deadline: Funding for MiniMed 770G consumables ended on 1 October 2026, moving remaining users onto Tandem or YpsoPump systems, which are the two funded pump brands.
• Regional growth gap: Stats NZ reported in October 2025 that Canterbury grew 1.1% to 698,200 people, the fastest of any region, while Wellington was flat at 0.0%.

New Zealand Diabetes Devices Market Size and Forecast

The market is moving from reactive, finger-prick monitoring towards continuous sensing and automated insulin delivery, with purchasing decisions made largely by the national funder rather than by individual buyers. Continuous glucose monitoring systems lead in value, while insulin pumps and consumables advance fastest as funded pump users move to supported platforms. Type 1 diabetes anchors revenue today, and type 2 diabetes grows quickest if sensor access widens. Community pharmacies remain the main route to patients, and online and direct supply gains share through supplier support portals and app-led onboarding. Auckland remains the largest region, and Canterbury grows quickest on faster population gains. Supplier mergers and clinic workforce limits point to a structural shift in product mix rather than a short cycle.

Key Takeaways: New Zealand Diabetes Devices Market

Public Funding Roughly Doubles the Market

Revenue is on course to expand by about 106% across the decade, from USD 215.00 million in 2025 to USD 443.12 million in 2035 at a 7.5% CAGR. Pharmac funding converts a meter-led market into a technology-led one.

Pumps and Type 2 Access Lead Growth

Continuous Glucose Monitoring Systems hold the largest share, but Insulin Pumps and Consumables grow at an estimated 10.2% CAGR and Type 2 Diabetes at an estimated 8.9% CAGR through 2035. Pharmac began funding MyLife Orbit Soft infusion sets on 1 August 2026, and Dexcom's New Zealand arm has a type 2 submission under review.

Managed Transitions Reset Brand Positions

Pharmac is retiring older products on fixed dates, so suppliers and clinics must move thousands of users to newer platforms without gaps in therapy.

• MiniMed 770G consumables funding ended on 1 October 2026
• Dexcom G6 stops being funded in early 2027, with G7 or Libre 3 Plus as replacements
• Sensocard test strips were discontinued in February 2026, leaving CareSens N strips funded

New Zealand Diabetes Devices Market Report Summary

Key Insight

Funded sensors and pumps are replacing meters and strips as the core of diabetes care. Insulin-treated care anchors revenue today, while wider access for other patients is the main upside.

Key Trends in the New Zealand Diabetes Devices Market

The New Zealand diabetes devices market is being reshaped by scheduled funding transitions, product retirements, sole-supply listings and the move to newer sensor platforms.

October 2026 - Pharmac Ends Funding for MiniMed 770G Consumables

• Pharmac stopped funding Medtronic MiniMed 770G infusion sets and reservoirs on 1 October 2026, the deadline for users to move to another funded pump.
• Tandem and YpsoPump are the funded pumps, and switching needs a new Special Authority, with the four-year pump rule waived for this move.
• Users who cannot switch may apply through Pharmac's Exceptional Circumstances Framework.

August 2026 - Dexcom G6 Set to Leave the Funded List in Early 2027

• Pharmac said on 4 August 2026 that the supplier decided to stop supplying the Dexcom G6, so funding ends in early 2027.
• Dexcom G7 and FreeStyle Libre 3 Plus are the replacements, and both work with the funded insulin pumps.
• Pharmacists were asked to encourage patients to see their prescriber before the end of 2026.

February 2026 - Sensocard Test Strips Discontinued, CareSens N Strips Stay Funded

• A Pharmac update of 13 February 2026 said the supplier of Sensocard strips for visually impaired users had discontinued them.
• Pharmaco CareSens N strips remain funded, though the CareSens N voice meter is not currently funded.
• The supplier was exploring sourcing voice meters from Pharmaco.

May 2025 - FreeStyle Libre 2 Plus Becomes the Funded Stand-Alone Abbott Sensor

• Pharmac decided on 11 April 2025 to list the FreeStyle Libre 2 Plus, supplied by Abbott Laboratories NZ Limited, from 1 May 2025.
• It extends wear time to 15 days, and users needed a new prescription before the older Libre 2 left the list.
• Funding is limited to 28 sensors a year and 6 per prescription.

Key Insight

Scheduled funding changes, product retirements and sole-supply listings are the main structural forces, while clinic workforce limits constrain how fast patients can move to newer systems.

Recent Market Developments in the New Zealand Diabetes Devices Market

Recent developments, presented from the most recent, show new funded consumables, supplier packaging changes, a pump maker listing and a change of ownership for a funded pump brand.

August 2026 - Pharmac Funds MyLife YpsoPump Orbit Soft Infusion Sets

• Pharmac began funding MyLife YpsoPump Orbit Soft infusion sets with a flexible insertion on 1 August 2026, in four sizes.
• The listing gives YpsoPump users a flexible option.
• More consumables choice supports pump retention and recurring revenue as MiniMed 770G users switch platforms.

July 2026 - BD Insulin Pen Needles and Syringes Move to Embecta Packaging

• Pharmac said on 3 July 2026 that BD Ultra Fine syringes and BD Micro Fine pen needles were being sold in Embecta packaging from 1 July 2026.
• Pharmac said the packaging change does not alter the product, and BD listings remain so pharmacies can still claim.
• Pharmac flagged on 23 October 2026 that some Embecta syringe gauges may be in limited supply.

February 2026 - MiniMed Launches Its Share Offering Roadshow on Nasdaq

• MiniMed announced on 24 February 2026 a roadshow for 28,000,000 shares at an expected USD 25.00 to USD 28.00 each, to list as MMED.
• Medtronic expects to hold about 90% after the offering, so MiniMed becomes a separately financed diabetes pure play.
• Funded New Zealand users are moving to rival pumps.

April 2025 - Ypsomed Agrees to Sell Its Diabetes Care Business to TecMed AG

• Ypsomed announced on 22 April 2025 the sale of Ypsomed Diabetes Care AG to TecMed AG for up to CHF 420 million including an earn-out.
• The deal covers the mylife YpsoPump and mylife CamAPS FX system, which will be combined with TecMed's patch pump programme.
• A dedicated owner may sharpen support for funded pump users, who now form one of two supported pump options.

Key Insight

Newly funded consumables, supplier packaging changes and ownership shifts among pump makers show vendors repositioning for a market where the funder controls brand access and pace.

New Zealand Diabetes Devices Industry Segmentation

The Expert Market Research’s report on the New Zealand Diabetes Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Continuous Glucose Monitoring Systems
• Insulin Pumps and Consumables
• Blood Glucose Meters and Test Strips
• Insulin Pen Needles and Syringes
• Others

Continuous Glucose Monitoring Systems lead on value, in our estimate, because Pharmac funds stand-alone sensors for everyone with type 1 diabetes, including the FreeStyle Libre 2 Plus from May 2025, and the segment grows at an estimated 8.4% CAGR through 2035. Insulin Pumps and Consumables grow fastest at an estimated 10.2%, helped by MyLife Orbit Soft infusion sets funded from August 2026. Blood Glucose Meters and Test Strips lose share, with Sensocard strips discontinued in February 2026. Insulin Pen Needles and Syringes are steady, with Embecta packaging replacing BD from July 2026. Others include lancets and ketone testing supplies.

Market Breakup by Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Others

Type 1 Diabetes leads on value, in our estimate, because every New Zealander with it can obtain funded sensors, and funded pumps are targeted at it. Type 2 Diabetes grows fastest at an estimated 8.9% CAGR through 2035, since a peer-reviewed study published in January 2025 projected 502,358 people with diabetes by the early 2040s and Dexcom's New Zealand arm has a type 2 submission under review. Gestational Diabetes depends mainly on meters and strips in maternity care. Others include type 3c and monogenic forms, which Pharmac's April 2025 decision lists for sensor eligibility.

Market Breakup by Distribution Channel

• Community Pharmacies
• Hospitals and Specialist Clinics
• Online and Direct Supply
• Others

Community Pharmacies lead, in our estimate, because they dispense funded sensors in three-month supplies and process claims, and Pharmac asked pharmacists in August 2026 to steer Dexcom G6 users to their prescribers. Hospitals and Specialist Clinics apply for Special Authority and train pump users, although a University of Waikato article of February 2025 noted a chronic diabetes workforce shortage. Online and Direct Supply grows fastest at an estimated 8.6% CAGR through 2035, as supplier portals, support lines and app updates, such as the Libre app fix of October 2026, deepen direct contact. Others cover pharmacy-chain private sales.

Market Breakup by Region

• Auckland
• Wellington
• Canterbury
• Waikato
• Others

Auckland dominates, in our estimate, as New Zealand's largest city grew 1.0% in the year to June 2025 and is where Mediray runs its New Zealand office, and it grows at an estimated 7.0% CAGR through 2035 from a large base. Canterbury is the fastest-growing region at an estimated 8.2%, as Stats NZ reported in October 2025 that it grew 1.1% to 698,200 people. Waikato grows at 7.8%, with a University of Waikato project funded in February 2025 tracking device uptake by region and ethnicity. Wellington grows at 6.6% after flat population in the year to June 2025, and Others at 7.4%.

Competitive Landscape in the New Zealand Diabetes Devices Market

Competition combines global sensor makers, pump makers, meter suppliers and local distributors that win positions through Pharmac listings rather than open retail tenders. Entry barriers include funder approval, Special Authority criteria, app and pump compatibility, clinic training capacity and reliable supply.

Dexcom

Dexcom, headquartered in San Diego, California, sells the G7 and ONE+ continuous glucose monitors in New Zealand through its subsidiary New Zealand Medical & Scientific Limited, with funded access of up to 40 sensors a year. Dexcom reported on 12 February 2026 full-year 2025 revenue of USD 4.662 billion, including USD 1.327 billion internationally. Its New Zealand arm says a type 2 diabetes submission is under review with Pharmac.

Abbott

Abbott, headquartered in Abbott Park, Illinois, supplies FreeStyle Libre sensors in New Zealand through Abbott Laboratories NZ Limited and distributor Mediray. The FreeStyle Libre 2 Plus was funded from 1 May 2025, and the Libre 3 Plus serves funded pump users. Abbott reported on 22 January 2026 that fourth-quarter 2025 continuous glucose monitor sales reached USD 2.0 billion, up 15.0%.

Tandem Diabetes Care

Tandem Diabetes Care, headquartered in San Diego, California, makes the t:slim X2 pump, which Pharmac funds with its consumables. Tandem reported on 19 February 2026 worldwide 2025 sales of USD 1.015 billion, with international sales of USD 307.8 million, and began a global rollout of t:slim X2 integration with the FreeStyle Libre 3 Plus. MiniMed 770G users had to move to Tandem or YpsoPump by 1 October 2026.

TecMed AG

TecMed AG, a Swiss company, agreed on 22 April 2025 to buy Ypsomed Diabetes Care AG for up to CHF 420 million, bringing the mylife YpsoPump and mylife CamAPS FX system under its ownership. YpsoPump is one of two pumps Pharmac funds, and MyLife Orbit Soft infusion sets were funded from 1 August 2026. The FreeStyle Libre 3 Plus is an authorised sensor for the mylife system in New Zealand.

Other players operating in the New Zealand diabetes devices market include MiniMed, Embecta, Roche, i-SENS, and Mediray, alongside pharmacy wholesalers, independent distributors, private-label suppliers and online retailers supplying devices to pharmacies, clinics, hospitals and patients across New Zealand.

Key Insight

Competition rests on funder listings, device compatibility, clinic support and supply reliability rather than price alone, while ownership changes among pump makers could reshape positions.